On July 4th, Gelon Hui reported that Chengdu Shengnuo Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of Saintnuo Biotechnology (688117.SH), recently received the Approval Notice for the Listing Application of Citrate Abivertide Active Pharmaceutical Ingredient issued by the National Medical Products Administration. Citrate abivertide is used for perioperative antithrombotic treatment in PCI and can specifically bind to the GPⅡb/Ⅲa receptor, inhibiting platelet aggregation by blocking the binding of fibrinogen, von Willebrand factor, and other adhesion ligands to GPⅡb/Ⅲa. Citrate abivertide not only has a strong affinity for its target (i.e., it can inhibit platelet aggregation), but also inhibits the growth of vascular smooth muscle by inhibiting the vitronectin receptor, thereby preventing arterial reocclusion.
圣诺生物(688117.SH)：枸橼酸倍维巴肽原料药获得上市申请批准通知书
Shengnuo Biotechnology (688117.SH): The application for the listing approval of Citric Acid Bivalirudin active pharmaceutical ingredient has been obtained.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.